ALZN Alzamend Neuro
- 0.6106
- -0.0192-3.05%
Alzamend Neuro News
Nasdaq Hearings Panel Granted Alzamend's Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disor
Alzamend Neuro Announces Nasdaq Hearing Panel's Affirmative Decision
Alzamend Neuro Announces Nasdaq Hearing Panel's Affirmative Decision
Express News | Alzamend Neuro Announces Favorable Decision From Nasdaq Hearings Panel
Alzamend Neuro Unveils Updated Investor Presentation Outlook
Alzamend Neuro Announces Initial Closing of Private Placement
Alzamend Neuro Announces Initial Closing of Private Placement
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAethlon Medical (NASDAQ:AEMD) stock moved upwards by 129.0% to $2.7 during Friday's pre-market session. The company's market cap stands at $7.1 million. Novavax (NASDAQ:NVAX) shares rose 119.23
Alzamend Neuro Secures Strategic $25M Investment Deal
Alzamend Neuro Shares Are Trading Higher After the Company Entered Into a Securities Purchase Agreement With an Institutional Investor.
Alzamend Neuro Shares Are Trading Higher After the Company Entered Into a Securities Purchase Agreement With an Institutional Investor.
EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Announces Agreement For Registered Direct Offering And Concurrent Private Placement For An Aggregate Of Up To $25M
EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Announces Agreement For Registered Direct Offering And Concurrent Private Placement For An Aggregate Of Up To $25M
Alzamend Neuro Ends ATM Offering, Issues Forward-Looking Statements
Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
Alzamend Neuro, Inc. (NASDAQ:ALZN) made waves Tuesday when the company announced its decision to terminate its "at-the-market" equity offering program. Shares were down nearly 12% at last check. What
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major
12 Health Care Stocks Moving In Friday's After-Market Session
GainersNeuBase Therapeutics (NASDAQ:NBSE) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. Aptevo Therapeutics (
Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed higher by over 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders i
Alzamend Neuro(ALZN.US) 10% Shareholder Buys US$688.2 in Common Stock
$Alzamend Neuro(ALZN.US)$ 10% Shareholder AULT MILTON C III purchased 1,000 shares of common stock on Apr 19, 2024 at an average price of $0.6882 for a total value of $688.2.Source: Announcement What
Buy Rating Justified by Alzamend Neuro's Promising Alzheimer's Treatments and Attractive Valuation
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders inte
Alzamend Neuro(ALZN.US) 10% Shareholder Buys US$304.24 in Common Stock
$Alzamend Neuro(ALZN.US)$ 10% Shareholder AULT MILTON C III purchased 334 shares of Common Stock on Apr 1, 2024 at an average price of $0.9109 for a total value of $304.24.Source: Announcement What is
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million. Fresh2 Group
Analysis
Price Target
No Data
